Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P06889 (Mol)
 630,302 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The generation of a sustained antibody response requires the participation of MHC class II-restricted T helper cells. We have identified class II-restricted sequences by immunizing BALB/c (H-2d) mice with 108 overlapping synthetic pentadecapeptides covering the whole sequence of the measles virus fusion protein (MV-F). Several strong T cell epitopes were found including a major cluster of H-2d-restricted peptides between amino acids 256 and 305. Some of these peptides including peptide F(421-435) and F(256-270) induced MV-specific T lymphocytes in vivo while other H2d-restricted MV-F sequences did not. Immunization with mixtures of selected peptides indicated a hierarchy among H2d-restricted sequences due to competition between peptides. The dominant peptide F(421-435) impaired the response to other T cell epitopes including F(256-270). The response to F(91-105) was obliterated by F(421-435) and F(256-270) but not by peptides devoid of a T cell epitope. When BALB/c mice were immunized with the MV, the immunodominant sequence F(421-445) was identified which included the synthetic peptide F(421-435). Our data suggest that competition during processing and/or presentation between H2d-restricted peptides defines the immunodominant sequence of the viral protein. Even though only a single immunodominant region was defined after immunization with the MV, peptides from other regions were able to induce MV-specific T cell responses. This finding is of interest for the design of subunit vaccines in general and for studying MV-specific T helper cells in an animal model in particular.
Mol Immunol 1995 Jan
PMID:Intramolecular immunodominance and intermolecular selection of H2d-restricted peptides define the same immunodominant region of the measles virus fusion protein. 787 57

Major histocompatibility complex (MHC) class II deficiency, or bare lymphocyte syndrome (BLS), is a disease of gene regulation. Patients with BLS have been classified into at least three complementation groups (A, B, and C) believed to correspond to three distinct MHC class II regulatory genes. The elucidation of the molecular basis for this disease will thus clarify the mechanisms controlling the complex regulation of MHC class II genes. Complementation groups B and C are characterized by a lack of binding of RFX, a nuclear protein that normally binds specifically to the X box cis-acting element present in the promoters of all MHC class II genes. We have now purified RFX to near homogeneity by affinity chromatography. Using an in vitro transcription system based on the HLA-DRA promoter, we show here that extracts from RFX-deficient cells from patients with BLS (BLS cells) in groups B and C, which are transcriptionally inactive in this assay, can be complemented to full transcriptional activity by the purified RFX. As expected, purified RFX also restores a completely normal pattern of X box-binding complexes in these mutant extracts. This provides the first direct functional evidence that RFX is an activator of MHC class II gene transcription and that its absence is indeed responsible for the regulatory defect in MHC class II gene expression in patients with BLS.
Mol Cell Biol 1994 Oct
PMID:Functional complementation of major histocompatibility complex class II regulatory mutants by the purified X-box-binding protein RFX. 793 1

MHC class II immuno-deficiency is a rare autosomal recessive disease due to a defect in transacting genes, which control the expression of the entire family of MHC alpha and beta class II genes. Previous analyses classified cells from eight MHC class II-deficient patients and four experimental mutant cell lines into four complementation groups, pointing to the existence of a large number of regulatory genes. We conducted fusion experiments with cell lines from two-thirds of all known patients and found that two complementation groups accounted for 20 of the 22 cases studied. These two complementation groups correspond closely to two ethnic groups: most patients of north African origin were classified into one group, while all patients originating from Spain were classified into a second main group. This suggests the existence of restricted number of ancestor mutations leading to this disease.
Hum Mol Genet 1994 Jun
PMID:Two complementation groups account for most cases of inherited MHC class II deficiency. 795 Dec 44

Postcapillary endothelium at the sites of inflammation undergoes a series of changes collectively termed endothelial cell activation. Activated endothelium expresses immunologically relevant surface proteins that include MHC class II antigens (Ags) and adhesion proteins, as well as exhibits a number of functional changes. Endothelial activation has not been thoroughly studied in CNS endothelium. We have examined cytokine-mediated endothelial activation in isolated rat CNS microvessels. Freshly isolated rat CNS microvessels are viable in culture for at least 72 h. Untreated microvessels express no endothelial activation antigens, but do exhibit constitutive expression of the transferrin receptor (tfR). INF gamma induces a dose-dependent increase in both MHC class II antigens and tfR measured by immunofluorescent staining and quantitated by laser cytometry. IFN gamma-mediated endothelial cell activation could be inhibited with as little as 2 ng/mL TGF-beta 1. although 100% inhibition was seen with 10 ng/mL TGF-beta 1. Cytokine-preactivated endothelial expression of class II Ag and tfR could also be inhibited by TGF-beta 1. TGF-beta 1-treated microvessels become anergic to IFN gamma stimulation. Results suggest that TGF-beta 1 may have a regulatory role in endothelial activation.
Mol Chem Neuropathol 1994 Aug
PMID:Transforming growth factor beta 1 inhibits cytokine-induced CNS endothelial cell activation. 799 25

Transport of mRNA from the nucleus to the cytoplasm is still a poorly understood process in which RNA signal sequences and cognate RNA-binding proteins may be involved. We have analysed the transport of the mRNA encoded by HLA-DRA, a member of the immunologically important MHC class II multigene family. We report that, in transient transfection experiments, HLA-DRA mRNA molecules encompassing a signal situated in the 3' untranslated region predominantly accumulate in the nucleus. We also show that the RNA sequence involved interacts with compartmentalized proteins of either nuclear or cytoplasmic origin. Deletion of the mRNA region encompassing this retention site results both in the abrogation of protein binding and in the release of HLA-DRA mRNA into the cytoplasm. In addition, we have found that the distribution of these HLA-DRA mRNA binding proteins is different in different cell types; in particular, their pattern of expression in Ntera-2, a human teratocarcinoma cell line, is distinct from that observed in Raji, a human B-lymphoma cell line, and is modulated by growth in retinoic acid. We conclude that recognition of a mRNA retention signal by proteins located in different compartments on either side of the nuclear membrane may regulate the nucleo-cytoplasmic partitioning of HLA-DRA transcripts and, perhaps, of MHC class II mRNA in general.
J Mol Biol 1994 Jul 15
PMID:Control of nucleo-cytoplasmic HLA-DRA mRNA partitioning by interaction of a retention signal with compartmentalized proteins. 802 4

A staged pattern of cathepsin B cleavage of MHC class II alpha, beta-bound invariant (Ii) chain and release of fragments was defined. Charge-loss mutations in the Ii chain were created in three clusters of cathepsin B putative cleavage sites R78K80K83K86, K137K143, and R151K154. Products of HLA-DR1 alpha, beta and wild type (WT) or mutant Ii genes, co-transfected into COS1 cells, were cleaved by cathepsin B and immunoprecipitated by antibodies either to MHC class II chains or to different Ii epitopes. In WT Ii, cathepsin B digestion generated two forms of p21 Ii fragments: a p21 recognized by anti-C-terminus antibodies and a p21 recognized by an antibody to a determinant near the N-terminus. C-terminal p21 was released from MHC class II alpha, beta chains upon its formation while N-terminal p21 remained associated with MHC class II alpha, beta chains. Mutations at K137K143 inhibited the generation of N-terminal p21 by cathepsin B. Mutation at R78K80K83K86 led to an accumulation of MHC class II-bound N-terminal p21 without the appearance of MHC class II-bound p14, p10, and p6 fragments after cathepsin B digestion. These results indicate that cathepsin B cleaves wild type Ii first about K137K143 to produce a MHC class II-associated N-terminal p21, which is then cleaved about R78K80K83K86 to generate p14, p10 and finally p6 which still associates with MHC class II alpha, beta chains. This pattern of staged cleavage and release of Ii might be related to a concerted mechanism regulating the binding of antigenic peptides to MHC class II molecules.
Mol Immunol 1994 Jul
PMID:Cathepsin B cleavage and release of invariant chain from MHC class II molecules follow a staged pattern. 803 34

Quantitative assays to measure the binding of defined synthetic antigenic peptides and purified MHC class I molecules are described for several common human HLA-A alleles (A1, A2.1, A3, A11 and A24). Under appropriate conditions, the binding of radiolabeled peptides to purified MHC class I molecules is very effective, highly specific, and appears to be dependent on the specific sequence motif of the peptide as defined by critical anchor residue positions. Establishment and optimization of the assay reveals that a relatively high fraction of the MHC class I molecules isolated from EBV transformed B cell line sources is capable of binding exogenously added peptide. Scatchard analysis for all alleles yields 5-10% occupancy values. There is a stringent peptide size requirement that is reflected by the direct influence of peptide length on the binding affinity. The peptide-MHC class I interactions demonstrate remarkable similarity to peptide-MHC class II interactions, both in overall affinity and kinetic behavior. The immunological relevance of the peptide-MHC class I binding assay is also demonstrated by measuring the affinity of a panel of previously described HLA restricted peptides for their HLA restriction element. In 91% (10/11) of the cases, the peptides bound with affinities of 50 nM or less, and in the remaining 9% (1/11) of the cases, in the 50 to 500 nM range. Thus, these data provide the first quantitative estimate of what level of HLA-A binding affinity is associated with a diverse panel of immunodominant CTL epitopes in man.
Mol Immunol 1994 Aug
PMID:Peptide binding to the most frequent HLA-A class I alleles measured by quantitative molecular binding assays. 804 72

The binding of a T cell-presented peptide to MHC class II alpha,beta chains occurs as a concurrent process with the release of the associated invariant chain (Ii) by cathepsin B. Ii was digested by cathepsin B from solubilized, MHC class II alpha,beta,Ii complexes in the presence of N-hydroxysuccinimidyl-4-azidobenzoate-conjugated, 125I-labeled, influenza virus matrix (18-29) peptide. The peptide was crosslinked where it became bound. This HLA-DR1-restricted peptide bound about three times more efficiently to class II alpha,beta chains of DR1-positive B cells when present during cathepsin B digestion of Ii than when added afterward, also at pH 5.0. Binding was competed by similarly DR-restricted peptides. Cathepsin D cleaved Ii but did not enhance peptide binding. However, a trace level of cathepsin D, added to the assay for peptide binding in the presence of cathepsin B, further enhanced peptide binding about three times. These experiments support an hypothesis for the staged release of Ii fragments by cathepsin D and cathepsin B, catalyzing at one point the insertion of a peptide into the antigen binding site formed by class II alpha and beta chains.
Mol Immunol 1994 Mar
PMID:More efficient peptide binding to MHC class II molecules during cathepsin B digestion of Ii than after Ii release. 813 80

Using a panel of antibodies (Abs) and a lectin, normal human adult pituicytes were studied in neurohypophyses obtained from 29 patients at autopsy. The pituicytes reacted frequently with Abs against major histocompatibility complex (MHC) class II antigens (Ags), macrophage markers (KP.1, PG.M1, LN-5), an anti-vimentin Ab and a biotinylated lectin Ricinus communis agglutinin (RCA-1). The number of pituicytes immunostained for these reagents varied, with the notable exception of vimentin. MHC class II Abs (LN-3, CR3.43)-positive pituicytes were numerous in approximately half. Microscopically, MHC class II Ag was found in pituicytes of various shapes, and were identified in macrophage-typed pituicytes by electron microscopic immunohistochemistry. Glial fibrillary acidic protein was found in only a small number of pituicytes and was absent in cells labeled with MHC class II Abs or macrophage markers. The results indicate that the immunophenotype of human pituicytes is distinct from other glial cells of the central nervous system, with a considerable number of cells expressing MHC class II Ags and macrophage markers.
Virchows Arch B Cell Pathol Incl Mol Pathol 1993
PMID:An immunohistochemical study of human pituicytes demonstrating frequent expression of MHC class II antigens and macrophage markers. 814 59

We have isolated and characterized a new MHC class II transcription mutant cell line, called UV. This cell line was derived from the mouse B lymphoma A20 by UV light-induced mutagenesis and immunoselection for the loss of surface MHC class II molecules. It expresses only 5% of the level of MHC class II molecules on A20 and this is associated with a similar reduction of class II specific mRNA. This defect cannot be restored by the MHC class II transcription inducers, IL-4 and IFN gamma, confirming that the mutation acts at the transcription level. The mutation also affects MHC class I expression, but the transcription of class I molecules is not affected. In contrast, the expression of other markers, such as the invariant chain and the surface immunoglobulins G and M, is not modified. Such a variant should prove useful for the study of the transcription factors involved in the regulation of MHC class II expression.
Mol Immunol 1993 Nov
PMID:Isolation and characterization of a new murine MHC class II transcription mutant cell line. 823 29


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>